With one year until new rules on ‘high-risk’ AI systems take effect in the EU, pharmaceutical companies using AI in the ...

The new EU and US trade deal averts a ‘trade war’ and should in principle provide businesses with welcomed stability, even if ...

Countries impacted most by the effects of climate change can claim compensation from other countries responsible for ...

Construction firms, developers and investors must fully understand the new behaviours needed to make a success of using the updated Joint Contract Tribunal (JCT) target cost form of contract, an ...

Foreign nationals employed to work overseas for Australian businesses can be entitled to the benefits and protection of Australian employment law, including unfair dismissal protections, a recent Fair ...

A recent judgment underscores the separate legal identity of companies and shareholders and clarifies the extent to which companies, including those in the UK, can assert legal professional privilege ...

The release of a progress report highlighting the implementation of recommendations made by South Africa’s Zondo Commission of Inquiry in State Capture has received a mixed response.

A division of the Unified Patent Court (UPC) in Germany has banned a company from selling a product in the UK because it considers the product to infringe a European patent in force in the UK, even ...

Employers in Dubai can choose to pay employee salaries using cryptocurrencies following a recent ruling. In considering a dispute over the recovery of unpaid wages, the Dubai Court of First Instance ...

AI developers that obtain data from online sources to train ‘general purpose AI’ (GPAI) models must compile a list of the websites from which they sourced the most data – and publish it on their own ...

The UK’s national security investment screening regime is set for “pragmatic evolution” under plans outlined by the UK government, experts have said.

With one year until new rules on ‘high-risk’ AI systems take effect in the EU, pharmaceutical companies using AI in the process of drug development need clarity on whether the rules will apply to them ...